Nevro, Globus

Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical to acquire Nevro for $5.85 per share
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies,
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.
Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain for $250 million in cash. Audubon-based Globus (NYSE: GMED) will pay $5.85 per share for Nevro Corp. (NYSE: NVRO), representing a 17% premium to the company's closing stocking price on Wednesday.
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,
Globus Medical (GMED) Receives a Hold from Needham
In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...
Nasdaq2d
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, GMED should be on investors' short list. Before you invest in Globus Medical, Inc. (GMED), want to know the best stocks to buy ...
Hosted on MSN1d
Globus Medical reaffirms FY25 stand-alone EPS $3.40-$3.50, consensus $3.47
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
Analysts Are Bullish on Top Healthcare Stocks: Globus Medical (GMED), Zimmer Biomet Holdings (ZBH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and ...
Stifel maintains GMED buy rating, $92 target amid NVRO buyout
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...